Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union.
[ Study finds SRS alone results in less cognitive decline
The use of stereotactic radiosurgery (SRS) alone on patients with limited (one to three) brain metastases results in less cognitive deterioration than when combined with whole brain radiotherapy (WBRT), investigators have reported.
In a study led by Paul D. Brown, MD, director of the CNS stereotactic radiotherapy program at the University of Texas MD Anderson Cancer Center, researchers determined there was less cognitive deterioration in patients who underwent SRS alone after 3 months (64%), than in patients who underwent SRS plus WBRT (92%). ]
For full article on Medpage Today - replace 2 DOT's with periods in following:
And you have not even mentioned Methane-hydrides which according
to U.S. Energy Dept. Office of Fossil Energy...
"While global estimates vary considerably, the energy content of methane occurring in hydrate form is immense, possibly exceeding the combined energy content of all other known fossil fuels. However, future production volumes are speculative because methane production from hydrate has not been documented beyond small-scale field experiments. "
Accuray Incorporated has added a news release to its Investor Relations website.....
"Accuray Incorporated (NASDAQ: ARAY) announced today that new studies demonstrating the TomoTherapy® System's leading-edge adaptive therapy capabilities and value as a mainstream radiation therapy device were presented at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Washington, DC, July 31 - August 4, 2016. More than 35 studies evaluating the system were shared during poster and oral presentations. The TomoTherapy System is used worldwide to treat a wide range of cancer cases, from the routine to complex, with extreme precision."
Go to their website to see the rest of the press release. Seems like CEO, Josh Levine, is really concentrating on getting TomoTherapy systems into single vault sites.
Lourenco said on the call today that the tariffs are in place for 5 years before they come up for review.
The TomoTherapy System is the only radiation system specifically designed for image-guided intensity-modulated radiation therapy (IMRT). Leveraging a CT scanner-based platform, TomoHelicalTM mode enables continuous delivery from 360 degrees around the patient with highly conformal and homogeneous dose to the tumor. A clinician can also choose to deliver treatment from specific fixed angles via TomoDirectTM mode. These unique features, combined with daily 3D image guidance, enable physicians to efficiently deliver highly accurate, individualized dose distributions which precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue for a variety of cancer types, including breast cancer. This is especially important for women diagnosed with cancer in the left breast, where the tumor may be close to critical organs such as the heart.
The study titled, "Once Daily Accelerated Partial Breast Irradiation: Preliminary Results with Helical TomoTherapy," provides results for 111 patients treated with APBI following lumpectomy. It also demonstrated that:
- Delivering the dose once a day over 10 days (others studies use 10 fractions twice-daily) could be a contributing factor to better cosmetic outcomes and lower toxicity. This is made possible because of the integrated image guidance of the TomoTherapy System and its excellent dose homogeneity;
- Patient compliance was remarkable as all patients completed the treatment without interruption;
- Treatments were very well tolerated with minimal acute or late side effects.
- "The TomoTherapy System is proving itself to be an excellent breast radiotherapy device. In fact, some sites have purchased the system to use solely for breast radiotherapy," said Fabienne Hirigoyenberry-Lanson, PhD, vice president medical affairs, at Accuray. "Studies such as the one undertaken by Dr. de Paula and his colleagues reinforce the benefits which the TomoTherapy System can provide and highlight why customers worldwide rely on the system as their mainstream radiation treatment device."
SUNNYVALE, Calif., July 21, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today preliminary results from a prospective, phase II trial evaluating once-daily accelerated partial breast irradiation (APBI) in patients treated with the TomoTherapy® System. The study, published in the June issue of the peer-reviewed AntiCancer Research, International Journal of Cancer Research and Treatment, reported no recurrence of cancer in the treated breast at median follow-up of 34 months. Additionally, more than 95 percent of patients and their physicians rated cosmesis -- preservation of the normal appearance of the breast -- as good/excellent.
"The phase II trial results are very encouraging for a carefully selected patient population, and should be considered by all radiation oncologists when evaluating APBI treatments for their low-risk patients," said Prof. Ugo De Paula, Department of Radiation Oncology, San Giovanni-Addolorata Hospital, Rome-Italy. "In our experience we found there was extremely good patient compliance with their APBI treatment regimen because of a very short, 10-day schedule and well-tolerated treatments. We believe that using daily image guidance, which is unique to the TomoTherapy System, is essential for the precise identification of the tumor
bed and reproducibility of treatment."
User Satisfaction Ratings Exceed Industry Average for 11 Consecutive Quarters
SUNNYVALE, Calif., July 14, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems continue to set the standard for overall user satisfaction. The Accuray systems received the highest composite overall user satisfaction rating among radiation treatment delivery systems in the U.S., according to the Q2 2016 MD Buyline Market Intelligence BriefingTM. The most recent ratings trend also shows Accuray has achieved the highest ratings among industry peers over the past three years.
In rating the Accuray systems, MD Buyline reports the company obtained the highest scores in a majority of categories measured including system performance, system reliability, service response time and service repair quality. CyberKnife System users also "highly recommend" the InCiseTM Multileaf Collimator (MLC) noting "it makes the treatment time much more efficient." CyberKnife and TomoTherapy System users continued to "praise the high level of reliability afforded by Accuray systems."
"The independent MD Buyline report is further evidence we are succeeding with our strategy to drive innovative cancer care with a clear focus on customer satisfaction," said Joshua H. Levine, president and CEO of Accuray. "The feedback continues to validate the TomoTherapy System's functionality as a workhorse radiation oncology device while also highlighting the expanded efficiency of our next generation CyberKnife System equipped with an MLC. Our strong overall user satisfaction ratings are a major factor behind our growth in the marketplace."
Of all the boards I look at this has been the most informative. Because of you surf, liske, ironstrong and others I have held onto and increased my shares to 60,000 and I intend to hold and till shaeres get to at least $20 / share and maybe longer if dividends return. Thanks you all for your honest and well informed posts.
randell, I have been watching this company Nanabiotix for a year or so. The symbol is FR:NANO. It has traded for the past year mostly between 16-18 with a 52 week high of 20 and a low of approx.12.5. I have not figured out how to buy the stock. I think it only trades on the French Stock Market. There is a article about it in MedicalPhysicsweb the link is: http://medicalphysicswebDOTorg/cws/article/research/65392
Replace DOT with period. The technology is interesting. I first came across it when Drug Discovery News, DDNEWS, devoted an issue to Nano Medicine. This is the onr company that caught my attention.
FDA Clearance continued ..............
“The Radixact System gives the radiation therapy team expanded capabilities across the widest range of patient cases, from the routine to the most complex, with precision, speed and efficient workflows,” said Joshua H. Levine, president and chief executive officer of Accuray.
According to Jennifer Smilowitz, PhD, clinical associate professor University of Wisconsin School of Medicine and Public Health, who was involved in the development of the new radiation therapy technology, “The Radixact System builds upon the unique strengths of the TomoTherapy platform. Expanded delivery capabilities enable treatment with image-guided, intensity-modulated radiation therapy (IG-IMRT, an extremely accurate form of radiation therapy) to an expanded range of patients. New database features make the ring gantry-based system even easier to operate and integrate within a radiation oncology department.”
Accuray will initiate commercial release of the Radixact System late in the first quarter of fiscal year 2017 (July – September 2016).
Accuray Receives 510(k) FDA Clearance for the RadixactTM Image-Guided Radiation Therapy Platform and Integrated Software
Next Generation "Smart" System Enables Clinicians to Provide Highly Precise Treatment, Efficiently, for More Patients, Every Day
SUNNYVALE, Calif., June 27, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RadixactTM Treatment Delivery Platform. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray PrecisionTM Treatment Planning System and iDMSTM Data Management System. These next generation hardware and software solutions which, together, make up the new Radixact system, enable faster, more efficient delivery of extremely precise treatment to a wider range of cancer patients, including those undergoing retreatment. The new Radixact system represents a major step forward in the evolution of the TomoTherapy® System in treatment speed and ease of use.
Radixact(TM) Treatment Delivery System
The system features a more powerful linear accelerator, MVCT imaging and helical treatment delivery, so clinicians can apply highly conformal and homogenous dose distributions to any target volume, while precisely sparing normal healthy tissue during each treatment fraction. The new Accuray Precision Treatment Planning System with smart, automated workflows and midcourse decision-making tools, enables clinicians to adapt delivery to changes in tumor size, shape and location within the patient.